News2024-10-10T21:11:12-07:00

News

Alumnus Spotlight on Meet Vora

December 3rd, 2024|Alumni News|

GraphWear has raised $28 million in funding to date, enabling critical advancements in its technology and expanding its reach through clinical trials and strategic collaborations. As an MBC BioLabs alumnus, Meet’s story exemplifies the entrepreneurial spirit and dedication fostered by the MBC BioLabs community, reflecting how innovation can thrive from modest beginnings.

BridgeBio’s Attruby™ (acoramidis) approved by FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients

November 27th, 2024|Alumni News|

The U.S. Food and Drug Administration (FDA) approved Attruby™ (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.

OneSkin closes $20M series A investment round, fueling the future of skin longevity with advanced research

November 27th, 2024|Startup News|

OneSkin is a best-in-class biotech skin health brand on a mission to revolutionize how we age. Created by four pioneering female scientists - OneSkin believes in research first, products second. That's why its founders spent five years analyzing over 900 peptides before discovering OS-01, the first ingredient scientifically proven to reverse skin's biological age.

Myka Labs partners with Mayo Clinic to develop next-gen AI for surgery

November 25th, 2024|Startup News|

The Myka Labs-Mayo Clinic collaboration has a near-term focus on developing tools for gastroenterologists and surgeons performing procedures to diagnose and treat disease in the pancreas and other abdominal organs, with a longer-term view toward developing wide-ranging artificial intelligence-based innovations that positively impact patient care across a broad spectrum of medical conditions.

Dren Bio Announces Strategic Collaboration with Novartis

July 31st, 2024|Alumni News|

We are thrilled to share the news of a strategic collaboration between Dren Bio, one of our distinguished alumni, and Novartis to develop bispecific antibody therapies targeting cancer. This partnership, which builds on Dren Bio’s targeted myeloid engager and phagocytosis platform, includes an upfront payment of $150 million from Novartis, with $25 million as an equity investment.

We Are Proud to Announce our Partnership with HitGen to Accelerate Biotechnology Discovery!

April 1st, 2024|MBC Biolabs News|

LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, today announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).

Go to Top